US FDA approves AZ's Bydureon Pen as Lilly eyes GLP-1 market
The US FDA has approved a weekly single-use syringe for AstraZeneca’ Bydureon as Lilly reveals its ambition in the GLP-1 drug market.
Archives for March 5, 2014
Fresenius invests in Oz plant; says recalled mouldy cancer drugs no risk
Fresenius Kabi has announced plans for a new $47m (€34m) infusion products manufacturing and cancer drug compounding facility in Australia.
Harlan and Bertin team to target discovery and translational meds market
Harlan is looking to take advantage of a dearth of new products in pharma clients’ pipelines with an early drug development partnership with France’s Bertin Pharma.
CRO KCR expands further into Western Europe
European CRO KCR has registered two new entities in the UK and Germany, which adds to its presence in 18 countries in Europe as well as the US.
Anti-addiction formulation of super-strong opioid unclear
Addiction doctors have petitioned the US FDA to prevent Zohydro ER, the first single-entity hydrocodone painkiller, hitting the market this month citing its potential for abuse. Its maker, Zogenix, has been tight-lipped on whether the drug’s formulation...